Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa)

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 3, 2009, Pages 345-354

  Zhang, T T ^a   Song, M ^a   Hang, T J ^a   Xu, X F ^a   Wen, A D ^b   Yang, L ^b   Jia, L ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Benserazide; Co beneldopa; Drug drug interaction; Levodopa; Madopar; Pharmacokinetics; Talipexole

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CLENBUTEROL; TALIPEXOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDICATION; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL IRRITATION; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; OPEN STUDY; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TABLET; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; AZEPINES; BENSERAZIDE; CHINA; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; DOPAMINE AGENTS; DOPAMINE AGONISTS; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; LEVODOPA; MALE; TABLETS; TANDEM MASS SPECTROMETRY;

EID: 65549094183     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.01008.x     Document Type: Article

References (17)

1. Eriksen JL, Petrucelli L (2004) Parkinson's disease - molecular mechanisms of disease. Drug Discovery Today: Disease Mechanisms, 1, 399 405. (Pubitemid 41128942)
2. Riederer P, Gerlach M, Muller T et al. (2007) Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism & Related Disorders, 13, 466 479. (Pubitemid 350102310)
3. Guttman M, Kish SJ, Furukawa Y (2003) Current concepts in the diagnosis and management of Parkinson's disease. Canadian Medical Association Journal, 168, 293 301. (Pubitemid 36205197)
4. Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet, 1, 345 349. (Pubitemid 8024416)
5. Rinne UK (1989) Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology, 39, 336 339. (Pubitemid 19094721)
6. Kohono Y, Fukuzaki K, Kitahara K et al. (1997) Anti-tremor activity of talipexole produced by selective dopamine D2 receptor stimulation in cynomolgus monkeys with unilateral lesions in the ventromedial tegmentum. European Journal of Pharmacology, 319, 197 205. (Pubitemid 27056039)
7. Kakimura J, Kitamura Y, Takata K et al. (2001) Release and aggregation of cytochrome c and -synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. European Journal of Pharmacology, 417, 59 67. (Pubitemid 32299869)
8. Mizuno Y, Kawa H, Naknishi T et al. (1993) Preliminary study of B-HT 920, a novel dopamine agonist, for the treatment of Parkinson's Disease. Drug Investigation, 5, 186 192. (Pubitemid 23117891)
9. Benkert O, Müller-Siecheneder F, Wetzel H (1995) Dopamine agonists in schizophrenia: a review. European Neuropsychopharmacology, 5 (Suppl 43 53. (Pubitemid 26017259)
10. FDA (1999) FDA Guidance: in vivo drug metabolism/ drug interaction studies: study design, data analysis, and recommendations for dosing and labeling. Rockville : FDA. November.
11. Hang TJ, Zhang M, Song M et al. (2007) Simultaneous determination and pharmacokinetic study of roxithromycin and ambroxol hydrochloride in human plasma by LC-MS/MS. Clinica Chimica Acta, 382, 20 24. (Pubitemid 46782728)
12. Wu XL, Hang TJ, Shen JP et al. (2006) Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 41, 918 924.
13. Song M, Hang TJ, Wang Y et al. (2006) Determination of oleanolic acid in human plasma and study of its pharmacokinetics in Chinese healthy male volunteers by HPLC tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 40, 190 196. (Pubitemid 43061237)
14. Liu XD, Jia L (2007) The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies. Current Drug Metabolism, 8, 815 821. (Pubitemid 350238911)
15. Schuirmann DJ (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the bioequivalence of average bioavailability. Journal of Pharmacokinetic and Biopharmceutics, 15, 657 680. (Pubitemid 18102616)
16. FDA (2003) FDA Guidance: bioavailability and bioequivalence studies for orally administered drug products - general considerations. Rockville : FDA. March.
17. Jia L, Liu XD (2007) The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Current Drug Metabolism, 8, 822 829. (Pubitemid 350238912)